

Friday 9 December

12:00 - 14:00	Registration and lunch	
14:00 - 15:15	Session 1: EMPA-KIDNEY - background, trial conduct and primary outcome	
	Welcome and introduction	Colin Baigent and Martin Landray
	EMPA-KIDNEY design and baseline characteristics	Richard Haynes
	Primary outcome: overall and by components and subgroups	Will Herrington
15:15 - 15:45	Break	
15:45-17:00	Session 2: EMPA-KIDNEY - other outcomes, safety analyses and meta-analysis	
	Secondary and tertiary outcomes; safety and laboratory analyses	Richard Haynes
	Impact of diabetes on the effects of SGLT-2 inhibitors on kidney outcomes: a meta-analysis	Kaitlin Mayne
16:30 - 17:00	Discussion	

06:30 - 09:00	Registration and breakfast	
09:00 - 10:15	Session 3: Diabetes, blood pressure and heart failure - what's new from CTSU?	
	Relationship between blood pressure, kidney function and chronic kidney disease	Natalie Staplin
	Does an aspirin a day keep heart failure away?	Michelle Goonasekera
	GLP-1 agonists and ASCEND-PLUS	Marion Mafham
10:15 - 10:45	Break	
10:45 - 12:00	Session 4: Future work	
	Post-trial follow-up plans and future work	Sarah Ng
	BI 690517 in patients with CKD: a phase 2 trial	Peter Rossing
	Study of Heart and Kidney Protection with BI 690517	Parminder Judge
12:00 - 12:30	Discussion	
12:30 - 14:00	Lunch and depart	